11/11
09:25 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at B. Riley from $16.00 to $8.00. They now have a "buy" rating on the stock.
High
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at B. Riley from $16.00 to $8.00. They now have a "buy" rating on the stock.
11/8
02:32 pm
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Medium
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
11/7
02:34 pm
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Guggenheim from $18.00 to $8.00. They now have a "buy" rating on the stock.
Medium
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its price target lowered by analysts at Guggenheim from $18.00 to $8.00. They now have a "buy" rating on the stock.
11/6
10:15 am
tngx
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
07:07 am
tngx
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
High
Report
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights [Yahoo! Finance]
11/6
07:05 am
tngx
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
High
Report
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
11/6
07:00 am
tngx
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
High
Report
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
10/28
08:25 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Medium
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
9/10
01:32 pm
tngx
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data [Seeking Alpha]
Neutral
Report
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data [Seeking Alpha]
9/10
08:01 am
tngx
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
Low
Report
Tango Therapeutics, Inc. (NASDAQ: TNGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.
8/28
07:00 am
tngx
Tango Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Tango Therapeutics to Participate in Upcoming Investor Conferences